Aflac (AFL) Q3 2023: Japan Cancer Sales Jump 23% as Capital Deployment Strengthens Shareholder Returns

November 2, 2023 | By EarningsIQ Research

Japan’s cancer insurance sales surged, U.S. reserve releases drove margin expansion, and capital deployment accelerated with a 19% dividend hike and $700 million in buybacks. Strategic product refreshes and digital investments underpin long-term efficiency, while management signals confidence in capital strength and succession planning. Investors should watch for normalization in Japan’s paid-up policy impact and evolving regulatory risks in the U.S.

Summary

• Japan Distribution Momentum: Cancer insurance alliances and Japan Post drove significant sales acceleration.
• U.S. Reserve Release Impact: Lower hospitalizations and actuarial updates unlocked substantial margin gains.
• Capital Actions Intensify: Dividend increase and aggressive buybacks reinforce shareholder return commitment.

Business Overview

Aflac is a leading supplemental health and life insurer operating primarily in Japan and the U.S., generating revenue from insurance premiums and investment income. The business is anchored in third sector products (cancer, medical, accident insurance) in Japan and voluntary benefits (worksite and group insurance) in the U.S., with Japan contributing the majority of earnings and assets. Distribution channels include alliances with Japan Post, Daiichi Life, and banks in Japan, and brokers and agents in the U.S. Investment returns and prudent capital management are central to the business model.

Performance Analysis

Japan’s segment delivered a standout quarter, with sales up 12.4% year-over-year, led by a nearly 23% increase in cancer insurance sales. The Japan Post partnership was a major contributor, and alliances with Daiichi Life and Dido Life also supported growth. However, net earned premium declined 2.8%, reflecting ongoing paid-up policy impact and prior reinsurance actions. Persistency remained high at 93.5%, though modestly down as product refreshes led to elevated lapses. The benefit ratio fell, aided by favorable underwriting and a $205 million re-measurement gain stemming from updated actuarial assumptions under the new LDTI regime.

In the U.S. segment, sales rose 7.5%, with group life, disability, and network dental/vision initiatives driving scale. Net premium grew 3.2%. The benefit ratio dropped sharply to 35.9%, reflecting both reserve releases and subdued claims utilization. Expense ratios were pressured by a software write-down and ongoing investment in growth platforms, but underlying trends point to future operating leverage as new businesses scale. Investment income was robust in both geographies, buoyed by higher yields and alternatives performance. The company executed $700 million in share repurchases and announced a 19% dividend increase, signaling confidence in capital strength.

• Japan Cancer Sales Surge: Distribution strength and product refreshes powered a 23% YoY growth in cancer insurance sales.
• Reserve Releases Boost Margins: U.S. actuarial unlocks following lower hospitalizations drove margin expansion, with benefit ratios well below historical levels.
• Capital Deployment Accelerates: $700 million in buybacks and a 19% dividend hike reflect strong cash flow and disciplined capital management.

While headwinds from paid-up policies and FX persist, operating leverage and capital flexibility remain intact, positioning Aflac to sustain elevated shareholder returns even as normalization trends unfold in Japan.

Executive Commentary

Strategic Positioning

1. Japan Product and Distribution Leverage

Aflac’s alliance-driven model in Japan continues to deliver, with Japan Post’s return as a distribution powerhouse materially boosting cancer insurance sales. The company’s product refresh strategy—targeting both younger (under 50) and existing policyholders—has proven effective, as evidenced by 80% of refreshed Waze product sales going to younger demographics and strong concurrent third sector cross-sell rates. This positions Aflac to defend and grow its core franchise even as legacy paid-up policies mature.

2. U.S. Growth Initiatives and Operating Leverage

U.S. sales growth was supported by network dental, vision, and group life/disability—businesses that currently elevate expense ratios but are expected to scale and improve profitability over time. The company’s ability to bundle essential products for larger groups, and its focus on productivity improvements, signal a long-term effort to drive margin expansion through operational efficiency and product breadth.

3. Digital Transformation and Efficiency

Digitization is a key pillar in Japan, with ongoing investments in digital self-service, applications, and claims. While the pace is tempered by Japan’s paper-based healthcare system, the move to digital is expected to yield administrative savings and improved customer experience over several years. In the U.S., technology investments are also underway, though recent software write-downs highlight near-term cost pressures before efficiency gains are realized.

4. Capital Flexibility and Shareholder Return

Capital deployment is a clear priority, with the board approving a 19% dividend increase and maintaining historically high buyback levels. The company’s robust capital ratios (Japan SMR above 1,000%, U.S. RBC above 650%) provide ample buffer for both organic growth and tactical capital returns. Management remains disciplined, favoring organic growth and selective tuck-in acquisitions over large-scale M&A.

5. Risk Management and Hedging Evolution

Aflac continues to evolve its FX hedging program, moving from forwards to put options to lower tail risk and hedge costs, albeit with some increase in capital ratio volatility for small currency moves. This approach reflects a sophisticated risk management stance, balancing cost, capital efficiency, and economic value preservation for the core Japan business.

Key Considerations

This quarter’s results underscore the importance of product innovation, disciplined capital management, and operational adaptability for Aflac’s long-term value creation.

Key Considerations:

• Japan Paid-Up Policy Normalization: The drag from legacy paid-up policies should diminish after 2025, supporting more stable earned premiums.
• Regulatory Uncertainty in the U.S.: Potential tri-agency rules could impact hospital indemnity products, but Aflac’s history of adapting to pre-tax changes and product innovation mitigates long-term risk.
• Commercial Real Estate Portfolio Monitoring: CRE exposure remains a watchpoint, with $1 billion on the watch list and ongoing workouts, but conservative loan-to-value ratios and workout discipline limit immediate loss risk.
• Expense Ratio Trajectory: Investment in digital and new business platforms elevates expenses near-term, but operating leverage is expected as these initiatives scale.

Risks

Key risks center on regulatory changes in the U.S. (especially around pre-tax treatment and hospital indemnity), Japan’s macro and FX volatility, and ongoing headwinds from paid-up policy maturities. The commercial real estate portfolio, though actively managed, could see further impairments if market conditions deteriorate. Expense ratios may remain elevated if growth initiatives take longer to reach scale, and any reversal in favorable morbidity trends could pressure margins.

Forward Outlook

For Q4 2023, Aflac expects:

• Japan expense ratio to trend toward the low end of the 20–22% range.
• U.S. benefit ratio to remain materially below the 47–50% outlook range, excluding re-measurement gains.

For full-year 2023, management maintained a disciplined capital return posture with an increased dividend and continued buybacks:

• Dividend per share raised 19% for Q1 2024 to $0.50.
• Further reinsurance transactions planned for Q4 to optimize capital flexibility.

Management highlighted continued focus on digital transformation, capital deployment, and navigating regulatory risk, with expectations for paid-up policy drag to moderate after 2025.

• Japan Post alliance and product refreshes to drive further sales momentum.
• Expense ratio improvement expected as digital and growth initiatives mature.

Takeaways

Aflac’s Q3 demonstrates the power of its dual-market model, disciplined capital allocation, and product-led growth. Investors should monitor normalization trends in Japan and regulatory developments in the U.S., while capital deployment and digital transformation remain multi-year value drivers.

• Distribution and Product Innovation: Japan’s alliances and refreshed products are driving customer acquisition and cross-sell opportunities, offsetting legacy policy headwinds.
• Margin Expansion and Capital Strength: Reserve releases and subdued claims in the U.S. boosted earnings, while robust capital ratios enabled aggressive buybacks and dividend hikes.
• Future Watchpoints: Track the normalization of paid-up policy impact in Japan, the scaling of U.S. growth initiatives, and the evolution of regulatory risk in the U.S. voluntary benefits market.

Conclusion

Aflac’s third quarter marks a period of strong execution, highlighted by Japan’s sales resurgence, U.S. margin expansion from actuarial unlocks, and a clear commitment to shareholder returns. The company’s strategic focus on product, distribution, and digital efficiency positions it for continued resilience, though regulatory and macro risks warrant ongoing vigilance.

Industry Read-Through

Aflac’s results signal continued strength in the supplemental health insurance market in Japan, with alliances and product innovation driving growth despite demographic and policy maturity headwinds. The U.S. voluntary benefits sector is benefitting from subdued claims and the shift toward bundled offerings, though regulatory uncertainty around pre-tax benefits and hospital indemnity products could reshape the landscape for all players. Insurers with disciplined capital management and a track record of product adaptation are best positioned to navigate these cross-currents. The evolving approach to FX hedging and digital transformation at scale offers a template for peers seeking efficiency and resilience in a volatile macro environment. CRE portfolio pressures remain a sector-wide concern, but conservative underwriting and proactive management can mitigate systemic risk.

AFL Financials Insurance Capital Management Digital Transformation Cancer Insurance Japan Shareholder Returns